Hut 8 Corp vs Relay Therapeutics Inc. Common Stock — how do they compare? Hut 8 Corp trades at $79.33 (market cap $9.82B), while Relay Therapeutics Inc. Common Stock trades at $17.62 (market cap $3.82B). The key difference: Hut 8 Corp is far larger — about 2.6× Relay Therapeutics Inc. Common Stock's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| HUT | RLAY | |
|---|---|---|
Market Cap | $9.82B | $3.82B |
Volume | 10,272,678 | 4,332,079 |
Sector | Financials | Health |
52-Week High | $133.02 | $20.75 |
52-Week Low | $33.76 | $6.03 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $17.25B | $2.93B |
Signals from Pluang's Aura AI — not financial advice
HUT trades at $89.3, down 3.17% today, amid a bearish technical signal. The company reported a net loss of $226.15 million in 2025 with a negative net margin, though revenue grew to $235.12 million. Recent news highlights a $1.07 billion credit facility and AI infrastructure deals, fueling optimism. Analyst consensus is strongly bullish with a $156.79 price target.
The outlook balances strong analyst support and AI infrastructure growth potential against persistent losses and high valuation multiples. Key risks include execution on profitability and competitive pressures in the digital infrastructure space.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →